Vancomycin for ulcerative colitis with liver condition
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether the antibiotic vancomycin can help treat active ulcerative colitis in people who also have primary sclerosing cholangitis (a liver condition). Vancomycin may reduce inflammation in the gut by changing the bacteria in your intestines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need a confirmed diagnosis of both ulcerative colitis and primary sclerosing cholangitis.
- Your ulcerative colitis must be moderately to severely active.
- You cannot have taken antibiotics or probiotics in the last 4 weeks (for a substudy).
- You must not have severe liver disease (other than PSC), severe kidney problems, active infections, or hearing issues.
- You cannot be pregnant or breastfeeding, and you must not have a known allergy to vancomycin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether vancomycin, an antibiotic, can help children with an unusual type of colitis (inflammation of the colon). It's for kids aged 6-15 who are already scheduled for a colonoscopy.
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
This trial tests a new medicine, ENC1018, taken by mouth, for people with moderate to severe ulcerative colitis (UC) that hasn't improved with standard treatments. The goal is to see if it's safe and helps reduce symptoms.
This study tests an investigational drug called LIV001 for people with mild-to-moderate ulcerative colitis. It aims to see if the drug is safe and may help reduce inflammation in the colon.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.